Peer-Reviewed Journal Details
Mandatory Fields
Walsh, J;Gheorghe, CE;Lyte, JM;van de Wouw, M;Boehme, M;Dinan, TG;Cryan, JF;Griffin, BT;Clarke, G;Hyland, NP
2020
April
Journal of Pharmacy and Pharmacology
Gut microbiome-mediated modulation of hepatic cytochrome P450 and P-glycoprotein: impact of butyrate and fructo-oligosaccharide-inulin
Validated
Optional Fields
INTERNATIONAL SCIENTIFIC ASSOCIATION XENOBIOTIC-PROCESSING GENES AGE-RELATED-CHANGES CHAIN FATTY-ACIDS GERM-FREE-MICE CONSENSUS STATEMENT TRANSPORTER GENES DRUG-METABOLISM EXPRESSION MOUSE
Objectives Our objective was to demonstrate microbial regulation of hepatic genes implicated in drug metabolism and transport using germ-free (GF) mice and to explore the impact of a microbial metabolite, butyrate, and a prebiotic dietary intervention on hepatic gene expression in mice.Methods Using reverse-transcriptase PCR, we investigated cytochrome P450 (CYP) and multidrug-resistance protein 1 (MDR1) expression in conventional, GF and colonised GF mice. To investigate the effects of butyrate, sodium butyrate (3 g/l) was administered for 21 days to conventional or GF mice. In the prebiotic study, young adult and middle-aged mice received diet enriched with 10% fructo-oligosaccharide (FOS)-inulin for 14 weeks.Key findings Colonisation of GF animals normalised expression of Cyp3a11 and Mdr1b to conventional levels. Butyrate upregulated Cyp2b10 in conventional mice (P < 0.05) but overall did not induce widespread changes in hepatic genes. FOS-inulin increased Cyp3a13 expression and had the opposite effect on Mdr1a expression in young adult mice (P < 0.05). Age, on the other hand, influenced the prebiotic effect on Cyp2a4 expression (P < 0.01).Conclusion The expression of hepatic genes implicated in drug metabolism and transport displays sensitivity to the microbiome, microbiome-derived metabolites and a microbial-targeted intervention. Our study may provide the impetus to explore microbiota-targeted interventions in normalising host metabolic activity and reducing inter-individual variability in drug pharmacokinetics.
HOBOKEN
0022-3573
10.1111/jphp.13276
Grant Details